IN8bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INAB research report →
Range $4 – $4
Price Chart
About the company
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies.
- CEO
- William T.
- IPO
- 2021
- Employees
- 18
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on INAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.33M
- P/E
- -0.74
- Fwd P/E
- 4.34
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.47
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -91.18%
- ROIC
- -91.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,501,000+0.0%
- Op Income
- $-19,861,000
- Net Income
- $-19,440,000+36.1%
- EPS
- $-4.44+74.0%
- OCF Growth
- +47.4%
- FCF Growth
- +47.6%
- 52W High
- $2.73
- 52W Low
- $0.88
- 50D MA
- $1.13
- 200D MA
- $1.54
- Beta
- 0.30
- RSI (14)
- 66
- Avg Volume
- 59.50K
No earnings-call transcripts are available for INAB yet.
- Free Float
- 75.2%
- Shares Outstanding
- 9.59M
- Float Shares
- 7.21M
of shares held by institutions
19 13F filers
Buy/sell ratio 9.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Alyeska Investment Group, L.P. | 944.32K | 0 |
| Franklin Resources Inc | 914.53K | 0 |
| 683 Capital Management, LLC | 724.64K | 0 |
| Stonepine Capital Management, LLC | 695.29K | ▲ 31.88K |
| Vanguard Capital Management LLC | 88.86K | 0 |
| Bios Capital Management, LP | 80.96K | ▼ 86.85K |
| Geode Capital Management, LLC | 72.55K | ▼ 13.69K |
| Citadel Advisors LLC | 63.05K | ▲ 63.05K |
| Oppenheimer & Co Inc | 63.04K | ▲ 39.01K |
| Vanguard Fiduciary Trust Co | 43.57K | 0 |
| Two Sigma Advisers, LP | 36.35K | ▼ 9.40K |
| Captrust Financial Advisors | 33.30K | 0 |
Held by 18 ETFs
Biggest fund positions in INAB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 26 | FAIRBAIRN EMILY | other | 724,637 |
| May 9, 26 | Ho William Tai-Wei | other | 154,500 |
| May 9, 26 | Greenwood Luba | other | 22,000 |
| May 9, 26 | Lamb Lawrence | other | 54,000 |
| May 9, 26 | FAIRBAIRN EMILY | other | 22,000 |
| May 9, 26 | McCall Patrick | other | 56,250 |
| May 9, 26 | Rochlin Kate | other | 60,000 |
| May 9, 26 | Epperly Corinne | other | 22,000 |
| May 9, 26 | Brandt Peter C. | other | 22,000 |
| May 9, 26 | Graff Jeremy R. | other | 22,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INAB coverage
Recent articles, reports, and earnings notes.
No research on INAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INAB report →IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 6
IN8bio Highlights Glioblastoma Survival Data, Eyes Autoimmune T-Cell Engager Milestone
defenseworld.net · Sep 28
IN8bio to Present at Sidoti Small-Cap Virtual Conference
globenewswire.com · Sep 22
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 10
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
globenewswire.com · Sep 9
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
globenewswire.com · Jul 9
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
zacks.com · Jun 4
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
globenewswire.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.